Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CPS1 | P31327 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24745854 | 0.86 | HPGD (0.46) | ALDH1A1CNR1MEN1KMT2ATSHR | |
| SCHEMBL31464596 | 0.82 | POLB (0.40) | ALDH1A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL24746242 | 0.81 | HPGD (0.43) | ALDH1A1CNR1MEN1KMT2ATSHR | |
| SCHEMBL10060722 | 0.77 | CPS1 (0.44) | ALDH1A1CNR1ROCK1TSHRMAPT | |
| SCHEMBL24746079 | 0.76 | HPGD (0.48) | ALDH1A1CNR1MEN1KMT2ATSHR | |
| SCHEMBL31464800 | 0.76 | PARP1 (0.44) | PARP1MTNR1BALDH1A1MEN1KMT2A | |
| SCHEMBL31464809 | 0.75 | MTNR1B (0.48) | MTNR1BALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL24745867 | 0.74 | HPGD (0.41) | CNR1MEN1KMT2AHTT | |
| SCHEMBL24745881 | 0.73 | MEN1 (0.54) | ALDH1A1MEN1KMT2ATSHRMAPT | |
| SCHEMBL24745853 | 0.72 | MEN1 (0.53) | ALDH1A1CNR1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025064853-A1 | RIPK3 INHIBITORS AND METHODS OF USE | Momentum Therapeutics, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250092031-A1 | RIPK3 INHIBITORS AND METHODS OF USE | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092031-A1 | RIPK3 INHIBITORS AND METHODS OF USE | RIPK3, RIPK1, RIPK2 | PARP1 335/4885MTNR1B 4438/4885ALDH1A1 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.